PortfoliosLab logoPortfoliosLab logo
Neuronetics, Inc. (STIM)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US64131A1051
CUSIP
64131A105
IPO Date
Jun 28, 2018

Highlights

Market Cap
$99.70M
Enterprise Value
$95.62M
EPS (TTM)
-$0.58
Total Revenue (TTM)
$149.16M
Gross Profit (TTM)
$72.31M
EBITDA (TTM)
-$28.50M
Year Range
$0.80 - $4.85
Target Price
$8.00
ROA (TTM)
-27.55%
ROE (TTM)
-174.27%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Neuronetics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Neuronetics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Neuronetics, Inc. (STIM) has returned 5.07% so far this year and -60.60% over the past 12 months.


Neuronetics, Inc.

1D
14.17%
1M
8.21%
YTD
5.07%
6M
-46.89%
1Y
-60.60%
3Y*
-20.72%
5Y*
-35.01%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jun 28, 2018, STIM's average daily return is +0.03%, while the average monthly return is +1.50%. At this rate, your investment would double in approximately 3.9 years.

Historically, 40% of months were positive and 60% were negative. The best month was Aug 2020 with a return of +119.9%, while the worst month was Aug 2024 at -52.8%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, STIM closed higher 45% of trading days. The best single day was May 4, 2021 with a return of +39.2%, while the worst single day was Aug 12, 2024 at -58.2%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202651.45%-35.89%8.21%5.07%
202592.55%37.10%-13.41%19.02%-10.73%-10.74%25.79%-24.15%-18.02%-2.93%-43.77%-7.38%-14.29%
202417.24%-11.76%58.67%-29.20%-43.03%-6.25%3.89%-52.78%-13.96%35.56%-2.91%61.00%-44.48%
2023-14.41%-3.23%-48.86%-21.31%19.21%-21.25%-8.37%-16.75%-17.68%-14.81%58.26%59.34%-57.79%
2022-19.73%-6.70%-9.28%-19.47%9.84%19.78%29.91%-14.39%-10.92%4.72%88.59%9.39%54.04%
202158.69%-11.91%-20.35%-15.12%29.24%18.05%-17.23%-49.32%-2.38%-20.73%-25.58%15.25%-59.86%

Benchmark Metrics

Neuronetics, Inc. has an annualized alpha of -9.36%, beta of 1.34, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since June 29, 2018.

  • This stock participated in 138.53% of S&P 500 Index downside but only -22.41% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-9.36%
Beta
1.34
0.08
Upside Capture
-22.41%
Downside Capture
138.53%

Return for Risk

Risk / Return Rank

STIM ranks 12 for risk / return — in the bottom 12% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


STIM Risk / Return Rank: 1212
Overall Rank
STIM Sharpe Ratio Rank: 1212
Sharpe Ratio Rank
STIM Sortino Ratio Rank: 1212
Sortino Ratio Rank
STIM Omega Ratio Rank: 1515
Omega Ratio Rank
STIM Calmar Ratio Rank: 1010
Calmar Ratio Rank
STIM Martin Ratio Rank: 1313
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Neuronetics, Inc. (STIM) and compare them to a chosen benchmark (S&P 500 Index).


STIMBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.68

0.90

-1.58

Sortino ratio

Return per unit of downside risk

-0.90

1.39

-2.28

Omega ratio

Gain probability vs. loss probability

0.90

1.21

-0.31

Calmar ratio

Return relative to maximum drawdown

-0.83

1.40

-2.23

Martin ratio

Return relative to average drawdown

-1.34

6.61

-7.94

Explore STIM risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Neuronetics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Neuronetics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Neuronetics, Inc. was 98.38%, occurring on Nov 13, 2024. The portfolio has not yet recovered.

The current Neuronetics, Inc. drawdown is 96.14%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.38%Sep 11, 20181555Nov 13, 2024
-12.46%Jun 29, 201824Aug 2, 20184Aug 8, 201828
-6.68%Aug 13, 20185Aug 17, 20183Aug 22, 20188
-3.34%Aug 23, 20184Aug 28, 20181Aug 29, 20185
-2.39%Aug 30, 20182Aug 31, 20182Sep 5, 20184

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Neuronetics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Neuronetics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for STIM relative to other companies in the Diagnostics & Research industry. Currently, STIM has a P/S ratio of 0.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for STIM in comparison with other companies in the Diagnostics & Research industry. Currently, STIM has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items